Beth Overmoyer
Hematology & Oncology · Boston, MANPI 1801827209
Payments from drug & device makers
$712,599in general payments, 2019–2025
Across 60 payments — averaging $11,877 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$577K
- Deciphera Pharmaceuticals Inc.$92K
- Eisai Inc.$44K
- Gilead$12
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 8 | $577,321 |
| Deciphera Pharmaceuticals Inc. | 48 | $91,629 |
| Eisai Inc. | 3 | $43,636 |
| Gilead | 1 | $12 |
How this compares
$712,599 in reported general payments places this provider in the 80th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.